Navigation Links
SGX Presents Preclinical MET Data at AACR
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) presented abstract #4844 at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET), inhibits growth of human glioblastoma tumors in a mouse model," was presented in the afternoon poster session entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall B-F.

SGX's MET program comprises potent, selective ATP-competitive MET inhibitors, from which a number of drug-like compounds have been identified. The first development candidate, SGX523, demonstrated potent anti-tumor activity when dosed orally in various mouse models of human cancer including glioblastoma, gastric cancer and lung cancer. SGX's second development candidate, SGX126, is structurally distinct and may possess several advantages over SGX523, including the potential for a lower human dose.

"We are continuing to progress SGX126 towards IND submission, while evaluating additional follow-on compounds for our MET program," said Mike Grey, the CEO of SGX Pharmaceuticals.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been imp
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
5. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
10. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... for Bevasiranib Broadly Covers siRNA Targeting of, VEGF Expression, Further Strengthening ... ... MIAMI, March 18 OPKO Health, Inc. (Amex: OPK ),today announced ... and Trademark Office (USPTO) for methods related to the use and,administration of ...
... safety, effectiveness, and environmental impact of removing pollutant, ... ... products-, BOURNE, Mass., ... company has closed the first,tranche of a $2.5 million institutional financing ...
... Mich., March 18 Neogen Corporation,(Nasdaq: NEOG ) announces the following ... When: March 25, 2008 11:00 EDT, Where: ... Simply log on to the web at the address ... of Neogen Corporation, +1-800-234-5333. If you are unable to participate during ...
Cached Biology Technology:OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... from a mutation in one genome are complicated enough, ... genomes: the DNA in the nucleus and in the ... genomic disconnects cause disease. In a step in that ... traced one such incompatibility in fruit flies down to ...
... ten million, with dogs producing approximately 1,000 tonnes of excrement ... as a major source of the parasite egg, Toxocara ... humans. The aim of the study, led by Dr ... of Veterinary Sciences and published in the international scientific journal, ...
... Here,s another reason why you should include olive oil ... the Journal of Leukocyte Biology ... significantly reduces intestinal ischemia (restricted blood supply) and the ... returns). The compound, called "oleuropein aglycone," is the most ...
Cached Biology News:Mitochondrial mutations: When the cell's 2 genomes collide 2Mitochondrial mutations: When the cell's 2 genomes collide 3Caring for dogs to reduce spread of parasite eggs harmful to humans 2Olive oil component alleviates intestinal ischemia and reperfusion 2
... Adapted to Sf-900 II ... isolated from Spodoptera frugiperda ... cells (1). The Sf21 ... serum-free suspension culture in ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
MAGP-2 (C-19)...
... Immunogen: Synthetic peptide derived from ... junctophilin-2. Specificity: Specific for the ... controls: mouse skeletal muscle homogenates frozen ... Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at ...
Biology Products: